Impact Biomedical, Inc., a wholly owned subsidiary of DSS, Inc.
(NYSE American: DSS), along with its scientific research partner
Global Research and Discovery Group Sciences (GRDG), announced
today that it signed a license agreement with ProPhase Labs
(NASDAQ: PRPH) for Equivir, which has shown potential as a
treatment to limit the occurrence of or reduce the risk or severity
of viral outbreaks.
“We are excited to team up with ProPhase Labs, who will apply
its nearly three decades of experience enhancing the health of the
public to Equivir, which we believe to be a ground-breaking
treatment that will positively impact health in the US and
globally,” said Frank. D. Heuszel, CEO of DSS.
Clinical Human Trials to BeginThe agreement
between GRDG and ProPhase comes just prior to the beginning of
human clinical trials for Equivir, GRDG announced. GRDG has
contracted with ICON plc, the world's leading clinical
research organization.
“These next clinical trials are a vital step in the process,”
said Daryl Thompson, Impact BioLife’s Director of Scientific
Initiatives, and founder of the advanced research company GRDG
Sciences, LLC. “This is where all of the work, the planning and the
research meets the ultimate challenge. I am extremely optimistic
that these trials will go well for Equivir.”
Equivir Since 2019 Equivir as a treatment
against viral infections has received two U.S. patents and a
positive patentability report opening the door
for international patent possibilities. The composition is
believed to work by potentially blocking the entry of a virus into
host cells, which prevents infection and replication in those host
cells.
In addition to its potential use for the treatment of infection
caused by various serotypes of influenza and Rhinovirus, a common
viral infectious agent predominantly associated with the common
cold in humans, Equivir is also believed to block the entry of
Ebola virus into host cells which can prevent Ebola Virus Disease
(EVD) and Ebola Hemorrhagic fever (EHF). These diseases are rare,
but severe and often fatal in humans, particularly in sub-Saharan
Africa. Ebola has a 90-percent death rate, according to the World
Health Organization. Equivir also has possible use in the treatment
of infections caused by SARS COV2.
“We have seen the impact of a global virus over the past 24
months and now, more than ever, we need something that can
potentially battle a variety of viruses,” said GRDG's Chief
Scientific Advisor Dr. Roscoe M. Moore, Jr., United States
Assistant Surgeon General (Retired) and former Epidemic
Intelligence Service (EIS) Officer at U.S. Centers for Disease
Control and Prevention. “We are hopeful for Equivir’s use as
a deployable strategic defense for a broad spectrum of
infections.”
Working with ProPhaseEquivir is a blend of FDA
Generally Recognized as Safe (GRAS) eligible polyphenols. The
composition is projected to come in capsule form and be taken much
like a multivitamin. This fits in with ProPhase Labs’ three decades
of experience in researching, developing, distributing, marketing
and selling over-the-counter consumer healthcare products and
supplements.
“This licensing agreement with ProPhase Labs leverages its long
track record of experience in manufacturing, marketing and
distributing, which we believe will streamline the manufacturing
and go to market process, allowing Equivir to be quickly
distributed when and where it is needed,” said Frank. D. Heuszel,
CEO of DSS.
About Impact BioMedical, Inc.Impact BioMedical,
Inc. ("Impact BioMedical") is a wholly owned subsidiary of DSS.
Impact BioMedical strives to leverage its scientific know-how and
intellectual property rights to provide solutions that have been
plaguing the biomedical field for decades. By tapping into the
scientific expertise of GRDG Sciences, LLC, Impact BioMedical
pledges to undertake a concerted effort in the R&D, drug
discovery and development for the prevention, inhibition, and
treatment of neurological, oncological and immuno related diseases.
For more information on Impact BioMedical visit
http://impbio.com/.
About DSS, Inc.DSS is a multinational company
operating business segments in blockchain security, direct
marketing, healthcare, consumer packaging, real estate, renewable
energy, securitized digital assets, securities trading and fund
management, and banking, lending, and finance. Its business model
is based on a distribution sharing system in which shareholders
receive shares in its subsidiaries as DSS strategically unlocks
value through IPO spinoffs. Under new leadership since 2019, DSS
has built the necessary foundation for sustainable growth through
the acquisition and formation of a diversified portfolio of
companies positioned to drive profitability in five high-growth
sectors. These companies offer innovative, flexible, and real-world
solutions that not only meet customer needs, but create sustainable
value and opportunity for transformation.
For more information on DSS visit http://www.dssworld.com
Investor Contact:Dave Gentry, CEORedChip Companies
Inc.407-491-4498DSS@redchip.com
Safe Harbor DisclosureThis press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Such forward-looking
statements include, but are not limited to, statements related to
the Company's intended use of proceeds and other statements that
are not historical facts. Forward-looking statements are based on
management's current expectations and are subject to risks and
uncertainties that may cause actual results or events to differ
materially from those projected. These risks and uncertainties,
many of which are beyond our control, include: risks relating to
our growth strategy; our ability to obtain, perform under and
maintain financing and strategic agreements and relationships;
risks relating to the results of development activities; our
ability to attract, integrate and retain key personnel; our need
for substantial additional funds; patent and intellectual property
matters; competition; as well as other risks described in our SEC
filings, including, without limitation, our reports on Forms 8-K,
10-K and 10-Q, all of which can be obtained on the SEC website at
www.sec.gov. Readers are cautioned not to place undue reliance on
the forward-looking statements, which speak only as of the date on
which they are made and reflect management's current estimates,
projections, expectations, and beliefs. We expressly disclaim any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in our expectations or any changes in events,
conditions, or circumstances on which any such statement is based,
except as required by law.
DSS (AMEX:DSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
DSS (AMEX:DSS)
Historical Stock Chart
From Jul 2023 to Jul 2024